Biopharmx Corp (AMEX:BPMX) had its price target reduced by research analysts at Maxim Group from $3.00 to $1.50 in a report released on Wednesday. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 418.13% from the company’s previous close.
Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 25th.
Biopharmx Corp (AMEX:BPMX) opened at 0.2895 on Wednesday. The stock’s market cap is $21.46 million. The company’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.48. Biopharmx Corp has a one year low of $0.19 and a one year high of $0.90.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.